Abstract
The prevalence of chronic renal disease is increasing dramatically in industrialized nations. Recent surveys in Europe and the US show that about 10% of the total population are affected. Patients with end stage disease, necessitating dialysis or transplantation, are only the tip of the iceberg. Even with treatment these subjects suffer from a massive reduction in quality and quantity of life despite consuming a large proportion of healthcare expenditures. As quite effective treatment strategies are available to prevent progression there is a pressing clinical need for early detection, differential diagnosis and assessment of the individual prognosis of renal disease. The current gold standard is the measurement of serum creatinine; despite the fact this method has some major limitations. These can be partially overcome by the use of newer markers like Cystatin C. However, a major problem using this approach is the fact that serum creatinine and Cystatin C are markers of renal excretory function only and hence no differential diagnosis can be derived from them. Furthermore a single measurement is not sufficient to estimate the prognosis of an individual patient, especially in the early stages of the disease, making tailored treatment difficult. In this review we will summarize our current knowledge about the markers in use today and also provide information on new, potentially superior markers, which would enable a much more complete non-invasive assessment of a growing patient population.
Keywords: Chronic kidney disease, biomarkers, glomerular filtration rate, serum creatinine, proteinuria, tubulointerstitial damage
Current Medicinal Chemistry
Title: In Search for the Troponin of the Kidney
Volume: 16 Issue: 32
Author(s): S-J. Noppert and G. Mayer
Affiliation:
Keywords: Chronic kidney disease, biomarkers, glomerular filtration rate, serum creatinine, proteinuria, tubulointerstitial damage
Abstract: The prevalence of chronic renal disease is increasing dramatically in industrialized nations. Recent surveys in Europe and the US show that about 10% of the total population are affected. Patients with end stage disease, necessitating dialysis or transplantation, are only the tip of the iceberg. Even with treatment these subjects suffer from a massive reduction in quality and quantity of life despite consuming a large proportion of healthcare expenditures. As quite effective treatment strategies are available to prevent progression there is a pressing clinical need for early detection, differential diagnosis and assessment of the individual prognosis of renal disease. The current gold standard is the measurement of serum creatinine; despite the fact this method has some major limitations. These can be partially overcome by the use of newer markers like Cystatin C. However, a major problem using this approach is the fact that serum creatinine and Cystatin C are markers of renal excretory function only and hence no differential diagnosis can be derived from them. Furthermore a single measurement is not sufficient to estimate the prognosis of an individual patient, especially in the early stages of the disease, making tailored treatment difficult. In this review we will summarize our current knowledge about the markers in use today and also provide information on new, potentially superior markers, which would enable a much more complete non-invasive assessment of a growing patient population.
Export Options
About this article
Cite this article as:
Noppert S-J. and Mayer G., In Search for the Troponin of the Kidney, Current Medicinal Chemistry 2009; 16 (32) . https://dx.doi.org/10.2174/092986709789578150
DOI https://dx.doi.org/10.2174/092986709789578150 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design The Impact of Substance P on the Pathogenesis of Insulin Resistance Leading to Gestational Diabetes
Current Pharmaceutical Biotechnology Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology The Role of Vascular Cell Senescence in Atherosclerosis: Antisenescence as a Novel Therapeutic Strategy for Vascular Aging
Current Vascular Pharmacology Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design Analysis of Carotid Ultrasound Images for the Assessment of Stroke Risk Using Level Set Method
Current Medical Imaging Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Telomeres and their Role in Aging and Longevity
Current Vascular Pharmacology The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Microarray Applications in Occlusive Vascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Tissue Factor and Atherothrombosis
Current Pharmaceutical Design Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design The Peri-Viable Baby Down Under - An Australian Perspective on the "Grey Zone" of Viability
Current Pediatric Reviews